Visit COVID-19 resources

[Skip to Content]

Preservative free (PF) Trusopt® (dorzolamide hydrochloride) eye drops

May 13
2013

MSD has informed the Royal College of Ophthalmologists that there are now a limited number of preservative-free (PF) Trusopt® (dorzolamide hydrochloride) eye drops presently available in the UK. In light of this and the fact that it is a limited supply, The College would like to advise you of the recommended best use of this

  • 13 May 2013

O.N.E. Network Access

May 02
2013

College Membership confers free access to the American Academy of Ophthalmology O.N.E. Network. If you have forgotten your username or password, or need instructions on logging in to the O.N.E. Network, please e-mail [email protected] Full Text Access to Eight Ophthalmology Journals Full content of journals such as theofficial journal of the AAO, Ophthalmology, and the English

  • 2 May 2013

Vascular Endothelial Growth Factor (anti-VEGF) medicines administered intra-ocularly

May 01
2013

College Statement This statement refers only to injections of anti –Vascular Endothelial Growth Factor (anti-VEGF) medicines administered intra-ocularly directly through the conjunctiva and sclera using a sharp needle. This statement is the current College position and supersedes older statements on intraocular injections in the ARMD Guidelines for Management (2009) and Maximising Capacity in AMD Services

  • 1 May 2013

Vision standards for driving updated April 2013

Apr 12
2013

As part of the suite of Ophthalmic Services Guidance Chapters, this document attempts to address some issues about driving which frequently concern ophthalmologists in their day-to-day work. Rather than reiterating information from the Department for Transport (DfT) and the Driving and Vehicle Licensing Agency (DVLA) which is easily available, either through links in the document

  • 12 April 2013

Response to SMC Decision to accept Eylea for wet AMD

Apr 11
2013

Statement from The Royal College of Ophthalmologists The Royal College of Ophthalmologists welcomes the SMC decision to recommend Aflibercept (Eylea®) as a treatment for neovascular AMD. Aflibercept is a soluble vascular endothelial growth factor (VEGF) receptor fusion protein which binds to all forms of VEGF and inhibits its actions. This drug has been shown in

  • 11 April 2013